You are here: Industry Insights > Rheumatoid Arthritis

News List

Gilead’s oral JAK inhibitor filgotinib wins EU approval pharmatimes
September 30, 2020
Gilead Science’s Galapagos-partnered oral JAK inhibitor filgotinib has been approved by the European Commission under the brand name Jyseleca for the treatment of moderate-to-severe active rheumatoid arthritis (RA).
Gilead gets approval for Jyseleca (filgotinib) in Japan for rheumatoid arthritis expresspharma
September 27, 2020
Gilead Japan will hold marketing authorisation of Jyseleca in Japan while Eisai will be responsible for product distribution.
Lupin launches Leflunomide Tablets USP expresspharma
September 03, 2020
These tablets are indicated for the treatment of adults with active rheumatoid arthritis.
Kevzara fails in PhIII COVID-19 trial pharmatimes
September 02, 2020
Sanofi and Regeneron's rheumatoid arthritis drug Kevzara (sarilumab) has failed to hit targets in a late-stage trial involving patients hospitalised with COVID-19, signalling the end of its development in this area.
US FDA declines approval for Gilead’s rheumatoid arthritis drug, Filgotinib expresspharma
August 20, 2020
The US drug regulator has issued a complete response letter requesting data from the MANTA and MANTA-RAy studies and expressing concerns regarding the overall benefit/risk profile of the drug.
INST scientists formulate nanoparticle to reduce severity of rheumatoid arthritis expresspharma
July 14, 2020
The team prepared Zinc gluconate loaded chitosan nanoparticles using chitosan and sodium tripolyphosphate in double-distilled water, and zinc gluconate was simultaneously added along with the synthesis of chitosan nanoparticles.
Novel Antibody Drug Conjugate ABBV-3373 Shows Improvement in Rheumatoid Arthritis americanpharmaceuticalreview
June 19, 2020
AbbVie announced new data from a Phase 2a study of ABBV-3373, an investigational anti-tumor necrosis factor (TNF) Glucocorticoid Receptor Modulator (GRM) steroid antibody drug conjugate (ADC), in adult patients with ...
Branded digital support for rheumatoid arthritis patients in Japan looks competitive and encouraging expresspharma
April 30, 2020
According to GlobalData’s report, ‘Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2027, Japan contributed US$1.9bn to the global RA market sales in 2017, representing 8.0 per cent of total sales across the 8MM*.
Depression May Worsen QOL in Rheumatoid Arthritis Patients drugs
December 30, 2019
Patients with coexisting rheumatoid arthritis (RA) and depression tend to have higher disease activity and lower quality of life than patients without depression ...
FDA approves new line of methotrexate products for rheumatoid arthritis europeanpharmaceuticalreview
December 10, 2019
RediTrex, a new line of methotrexate products, has been approved by the FDA for the treatment of patients with rheumatoid arthritis.

Previous page 1 2 3 4 5 6 Next page